Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
In-person vs
Indication for SOLIQUA 100/33 SOLIQUA 100/33 (insulin glargine and lixisenatide) is a combination of insulin glargine, an insulin analog, and lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
I lost 5 pounds in 2 weeks with no side effects
As such, people who release insufficient amounts of GLP-1 may struggle with managing their weight and blood sugar
As Healio previously reported, the FDA removed tirzepatide (Mounjaro/Zepbound, Eli Lilly) and semaglutide (Ozempic/Wegovy, Novo Nordisk) from its drug shortage list in 2024 and 2025, respectively, and now prohibits both 503A compounding pharmacies and 503B outsourcing facilities from distributing compounded versions of the drug
US$ 23.05
US$ 29.81
US$ 26.03
US$ 25.89
